{"id":2020,"date":"2022-07-13T10:28:31","date_gmt":"2022-07-13T08:28:31","guid":{"rendered":"https:\/\/www.unioviedo.es\/IUOPA\/?p=2020"},"modified":"2023-03-09T14:55:38","modified_gmt":"2023-03-09T13:55:38","slug":"gran-avance-con-sello-asturiano-para-la-deteccion-de-tumores-malignos-de-tiroides","status":"publish","type":"post","link":"https:\/\/www.unioviedo.es\/IUOPA\/gran-avance-con-sello-asturiano-para-la-deteccion-de-tumores-malignos-de-tiroides\/","title":{"rendered":"Gran avance con sello asturiano para la detecci\u00f3n de tumores malignos de tiroides"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-justify-content-center\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><style type=\"text\/css\">@media only screen and (max-width:1024px) {.fusion-title.fusion-title-1{margin-top:0px!important; margin-right:0px!important;margin-bottom:20px!important;margin-left:0px!important;}}@media only screen and (max-width:640px) {.fusion-title.fusion-title-1{margin-top:0px!important; margin-right:0px!important;margin-bottom:20px!important; margin-left:0px!important;}}<\/style><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-one\" style=\"font-size:30px;margin-top:0px;margin-right:0px;margin-bottom:20px;margin-left:0px;\"><h1 class=\"title-heading-left fusion-responsive-typography-calculated\" style=\"margin:0;font-size:1em;--fontSize:30;line-height:1.1;\">Gran avance con sello asturiano para la detecci\u00f3n de tumores malignos de tiroides<\/h1><\/div><div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-zoomin\"><a href=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio.jpg\" class=\"fusion-lightbox\" data-rel=\"iLightbox[73ae87bf13428ff0fd7]\" data-title=\"cancer-tiroides-kpvH-U170696901677fZD-624&#215;385@El-Comercio\" title=\"cancer-tiroides-kpvH-U170696901677fZD-624&#215;385@El-Comercio\"><img decoding=\"async\" width=\"1600\" height=\"1078\" src=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio.jpg\" data-orig-src=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio.jpg\" alt class=\"lazyload img-responsive wp-image-2021\" srcset=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271600%27%20height%3D%271078%27%20viewBox%3D%270%200%201600%201078%27%3E%3Crect%20width%3D%271600%27%20height%3D%271078%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-srcset=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio-200x135.jpg 200w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio-400x270.jpg 400w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio-600x404.jpg 600w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio-800x539.jpg 800w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio-1200x809.jpg 1200w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2022\/07\/cancer-tiroides-kpvH-U170696901677fZD-624x385@El-Comercio.jpg 1600w\" data-sizes=\"auto\" data-orig-sizes=\"(max-width: 1024px) 100vw, (max-width: 640px) 100vw, 1200px\" \/><\/a><\/span><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><style type=\"text\/css\">@media only screen and (max-width:1024px) {.fusion-title.fusion-title-2{margin-top:0px!important; margin-right:0px!important;margin-bottom:31px!important;margin-left:0px!important;}}@media only screen and (max-width:640px) {.fusion-title.fusion-title-2{margin-top:0px!important; margin-right:0px!important;margin-bottom:20px!important; margin-left:0px!important;}}<\/style><div class=\"fusion-title title fusion-title-2 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"font-size:20px;margin-top:0px;margin-right:0px;margin-bottom:31px;margin-left:0px;\"><h2 class=\"title-heading-left fusion-responsive-typography-calculated\" style=\"margin:0;font-size:1em;letter-spacing:0px;--fontSize:20;--minFontSize:20px;line-height:1.3;\"><span style=\"font-family: Roboto Slab;\">La investigaci\u00f3n ha descubierto nuevos biomarcadores epigen\u00e9ticos de c\u00e1ncer de tiroides que podr\u00edan facilitar el diagn\u00f3stico de pacientes con citolog\u00edas indeterminadas<\/span><\/h2><\/div><div class=\"fusion-text fusion-text-1\"><p class=\"voc-paragraph\">Investigadores asturianos del Instituto de Investigaci\u00f3n del Principado de\u00a0<strong>Asturias<\/strong>\u00a0(ISPA), el Hospital Universitario de Asturias (\u00a0<a title=\"HUCA\" href=\"https:\/\/www.elcomercio.es\/temas\/entidades\/huca.html\" data-voc-vtm-id=\"in-text-traffic\">HUCA<\/a>), el Instituto de Universitario de Oncolog\u00eda de Asturias (Iuopa), el Centro de Investigaci\u00f3n Biom\u00e9dica en Red (Ciberer) y el Centro de Investigaci\u00f3n de Nanomateriales y Nanotecnolog\u00eda (CINN-\u00a0<a title=\"CSIC\" href=\"https:\/\/www.elcomercio.es\/temas\/entidades\/csic.html\" data-voc-vtm-id=\"in-text-traffic\">CSIC<\/a>) han descubierto nuevos biomarcadores epigen\u00e9ticos de c\u00e1ncer de tiroides que podr\u00edan facilitar el diagn\u00f3stico de pacientes con citolog\u00edas indeterminadas.<\/p>\n<p class=\"voc-paragraph\">El trabajo, recientemente publicado en la revista internacional &#8216;European Journal of Endocrinology&#8217; recoge las claves de este descubrimiento multidisciplinar que ha involucrado a profesionales de servicios de salud y biobancos de toda Espa\u00f1a.<\/p>\n<p class=\"voc-paragraph\">Aproximadamente el 60% de los\u00a0<strong>n\u00f3dulos tiroideos<\/strong>\u00a0se diagnostican correctamente como benignos, eliminando as\u00ed la necesidad de cirug\u00eda, ha explicado el ISPA en nota de prensa. Sin embargo, existe una zona gris, con aproximadamente el 30% de los casos indeterminados, en el que a pesar de que la mayor\u00eda de estos tumores se extirpan quir\u00fargicamente, solo un peque\u00f1o n\u00famero resultar\u00e1 positivo para malignidad.<\/p>\n<p class=\"voc-paragraph\">Una de las mayores limitaciones en la pr\u00e1ctica cl\u00ednica, ha explicado el jefe de Secci\u00f3n de diabetes del Servicio de Endocrinolog\u00eda del HUCA, El\u00edas Delgado, radica en la falta de marcadores inmunohistoqu\u00edmicos adecuados para distinguir entre el carcinoma folicular de tiroides y otros tipos de lesiones benignas, lo cual \u00abcomplica\u00bb el diagn\u00f3stico.<\/p>\n<p class=\"voc-paragraph\">El objetivo del trabajo se centr\u00f3 en el an\u00e1lisis molecular de distintas capas -\u00f3micas con el fin de identificar nuevos biomarcadores asociados con la malignidad. Para poder realizar los an\u00e1lisis con garant\u00edas, la obtenci\u00f3n de una poblaci\u00f3n de muestras representativa fue una parte clave del estudio.<\/p>\n<p class=\"voc-paragraph\">\u00abNos pusimos en contacto con la red de biobancos espa\u00f1ola para recopilar todas las muestras disponibles y poder llevar a cabo este trabajo\u00bb indica Paula Morales S\u00e1nchez, investigadora predoctoral AECC que desarrolla su tesis en el ISPA.<\/p>\n<p class=\"voc-paragraph\">\u00abEn este trabajo hemos analizado datos de epigenomas completos de adenomas y carcinomas de tiroides y hemos supervisado dichos an\u00e1lisis con herramientas de inteligencia artificial. Gracias a ello hemos podido identificar un n\u00famero muy reducido de biomarcadores epigen\u00e9ticos que predicen con una alta especificidad y sensibilidad la malignidad de una muestra determinada\u00bb, explican Juan Ram\u00f3n Tejedor y Agust\u00edn Fern\u00e1ndez, investigadores del CSIC-ISPA encargados de los an\u00e1lisis de este estudio.<\/p>\n<p class=\"voc-paragraph\">Sandra Rodr\u00edguez-Rodero, primera firmante del art\u00edculo, agrega que estas observaciones fueron validadas mediante distintas aproximaciones experimentales. \u00abLa aplicabilidad de este descubrimiento radica en su f\u00e1cil implementaci\u00f3n con tecnolog\u00edas de cribado molecular, tales como la tecnolog\u00eda de pirosecuenciaci\u00f3n, que podr\u00eda resultar en un m\u00e9todo complementario de diagn\u00f3stico cl\u00ednico con potencial inter\u00e9s para el Sistema Nacional de Salud\u00bb, ha explicado.<\/p>\n<p class=\"voc-paragraph\">El subdirector cient\u00edfico del ISPA, Mario Fern\u00e1ndez Fraga, se ha mostrado satisfecho con el hallazgo, ya que se ha podido clasificar \u00abde manera precisa\u00bb el potencial de malignidad del conjunto de tumores benignos o adenomas, y han observado que algunos de ellos ya muestran caracter\u00edsticas claras de malignidad en estad\u00edos tempranos.<\/p>\n<p class=\"voc-paragraph\">Este trabajo ha recibido financiaci\u00f3n de la AECC, el Instituto de Salud Carlos III, el IUOPA, la Universidad de Oviedo, el PCTI del Principado de Asturias, con fondos de cofinanciaci\u00f3n FEDER y la Fundaci\u00f3n General CSIC.<\/p>\n<p>Fuente: <a href=\"http:\/\/www.elcomercio.es\" target=\"_blank\" rel=\"noopener\">El Comercio<\/a><\/p>\n<p><a href=\"https:\/\/www.elcomercio.es\/sociedad\/salud\/cancer-tiroides-asturias-avance-detectar-tumores-malignos-20220712114504-nt.html\" target=\"_blank\" rel=\"noopener\">Leer noticia<\/a><\/p>\n<\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-0{width:75% !important;order : 0;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.56%;margin-left : 2.56%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;order : 0;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 0px;margin-top : 0px;padding-right : 30px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 30px;}@media only screen and (max-width:1024px) {.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 80px;}}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 20px 0px 20px 0px;\"><div class=\"fusion-sharing-box fusion-sharing-box-1\" style=\"background-color:#f6f6f6;margin-top:60px;\" data-title=\"Gran avance con sello asturiano para la detecci\u00f3n de tumores malignos de tiroides\" data-description=\"La investigaci\u00f3n ha descubierto nuevos biomarcadores epigen\u00e9ticos de c\u00e1ncer de tiroides que podr\u00edan facilitar el diagn\u00f3stico de pacientes con citolog\u00edas indeterminadas \r\nInvestigadores asturianos del Instituto de Investigaci\u00f3n del Principado de\u00a0Asturias\u00a0(ISPA), el Hospital Universitario de Asturias (\u00a0HUCA), el Instituto de Universitario de Oncolog\u00eda de Asturias (Iuopa), el\" data-link=\"https:\/\/www.unioviedo.es\/IUOPA\/gran-avance-con-sello-asturiano-para-la-deteccion-de-tumores-malignos-de-tiroides\/\"><h4 class=\"tagline\" style=\"color:#2f2f2f;\">Compartir noticia<\/h4><div class=\"fusion-social-networks sharingbox-shortcode-icon-wrapper sharingbox-shortcode-icon-wrapper-1\"><span><a href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.unioviedo.es%2FIUOPA%2Fgran-avance-con-sello-asturiano-para-la-deteccion-de-tumores-malignos-de-tiroides%2F&amp;t=Gran%20avance%20con%20sello%20asturiano%20para%20la%20detecci%C3%B3n%20de%20tumores%20malignos%20de%20tiroides\" target=\"_blank\" rel=\"noreferrer\" title=\"Facebook\" aria-label=\"Facebook\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-facebook awb-icon-facebook\" style=\"color:#76b5ae;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/twitter.com\/share?text=Gran%20avance%20con%20sello%20asturiano%20para%20la%20detecci%C3%B3n%20de%20tumores%20malignos%20de%20tiroides&amp;url=https%3A%2F%2Fwww.unioviedo.es%2FIUOPA%2Fgran-avance-con-sello-asturiano-para-la-deteccion-de-tumores-malignos-de-tiroides%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Twitter\" aria-label=\"Twitter\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-twitter awb-icon-twitter\" style=\"color:#76b5ae;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/www.linkedin.com\/shareArticle?mini=true&amp;url=https%3A%2F%2Fwww.unioviedo.es%2FIUOPA%2Fgran-avance-con-sello-asturiano-para-la-deteccion-de-tumores-malignos-de-tiroides%2F&amp;title=Gran%20avance%20con%20sello%20asturiano%20para%20la%20detecci%C3%B3n%20de%20tumores%20malignos%20de%20tiroides&amp;summary=La%20investigaci%C3%B3n%20ha%20descubierto%20nuevos%20biomarcadores%20epigen%C3%A9ticos%20de%20c%C3%A1ncer%20de%20tiroides%20que%20podr%C3%ADan%20facilitar%20el%20diagn%C3%B3stico%20de%20pacientes%20con%20citolog%C3%ADas%20indeterminadas%20%0D%0AInvestigadores%20asturianos%20del%20Instituto%20de%20Investigaci%C3%B3n%20del%20Principado%20de%C2%A0Asturias%C2%A0%28ISPA%29%2C%20el%20Hospital%20Universitario%20de%20Asturias%20%28%C2%A0HUCA%29%2C%20el%20Instituto%20de%20Universitario%20de%20Oncolog%C3%ADa%20de%20Asturias%20%28Iuopa%29%2C%20el\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"LinkedIn\" aria-label=\"LinkedIn\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-linkedin awb-icon-linkedin\" style=\"color:#76b5ae;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"mailto:?subject=Gran%20avance%20con%20sello%20asturiano%20para%20la%20detecci%C3%B3n%20de%20tumores%20malignos%20de%20tiroides&amp;body=https%3A%2F%2Fwww.unioviedo.es%2FIUOPA%2Fgran-avance-con-sello-asturiano-para-la-deteccion-de-tumores-malignos-de-tiroides%2F\" target=\"_self\" title=\"Correo electr\u00f3nico\" aria-label=\"Correo electr\u00f3nico\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-mail awb-icon-mail\" style=\"color:#76b5ae;\" aria-hidden=\"true\"><\/i><\/a><\/span><\/div><\/div><style type=\"text\/css\">.fusion-sharing-box-1 h4{margin-bottom:0 !important;}.fusion-sharing-box-1{flex-direction:row !important;padding-top:20px !important;padding-bottom:20px !important;}.sharingbox-shortcode-icon-wrapper-1 span.sharingbox-shortcode-icon-separator{border-right-width:0px !important;}@media only screen and (max-width:1024px){.fusion-sharing-box-1 h4{margin-right:0.5em !important;margin-bottom:0 !important;}.sharingbox-shortcode-icon-wrapper-1{width:auto !important;justify-content:flex-end !important;}.fusion-sharing-box-1{align-items:center !important;} }@media only screen and (max-width:640px){.fusion-sharing-box-1{flex-direction: column !important;align-items:center !important;}.fusion-sharing-box-1 h4{margin-bottom:revert !important;}.sharingbox-shortcode-icon-wrapper-1{width:100% !important;justify-content:space-between !important;} }<\/style><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 20px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 20px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 0px;margin-top : 0px;padding-right : 30px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":2021,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241],"tags":[198],"class_list":["post-2020","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ultimas-noticias","tag-cancer-tiroides"],"_links":{"self":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/posts\/2020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/comments?post=2020"}],"version-history":[{"count":1,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/posts\/2020\/revisions"}],"predecessor-version":[{"id":2022,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/posts\/2020\/revisions\/2022"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/media\/2021"}],"wp:attachment":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/media?parent=2020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/categories?post=2020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/tags?post=2020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}